双歧杆菌与黄连素治疗高血糖有效性和安全性的随机对照试验研究方案
这是一项多中心、双盲、随机、平行对照试验,计划纳入300例新诊断的糖尿病前期或糖尿病患者,随机分入双歧杆菌组、黄连素组、双歧杆菌联合黄连素组和安慰剂对照组,治疗16周,主要结局为治疗16周后空腹血糖绝对值与基线的比较。该研究旨在确定双歧杆菌和黄连素降血糖效果及安全性。
要点
- 首个在新诊断糖尿病前期或糖尿病患者中评估双歧杆菌与黄连素降糖效果及安全性的随机对照试验。
- 研究为多中心、双盲、随机、平行对照设计,包含2周导入期和16周治疗期。
- 300例随机患者分四组:双歧杆菌、黄连素、双歧杆菌联合黄连素、安慰剂对照。
核心结论
- 该研究旨在确定双歧杆菌和黄连素对新诊断糖尿病前期或糖尿病患者的降血糖效果及安全性。
- 这是首个在新诊断糖尿病前期或糖尿病患者中评估双歧杆菌与黄连素降糖效果及安全性的随机对照试验。
- 研究结果可能为黄连素和双歧杆菌用于糖尿病治疗提供支持。
研究设计与样本
- 300例随机患者分入双歧杆菌组、黄连素组、双歧杆菌联合黄连素组和安慰剂对照组,治疗16周。
- 主要结局为治疗16周后空腹血糖绝对值与基线的比较。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Berberine is one of the most important examples of a Chinese traditional medicine that has hypoglycemic effects but there have been no randomized controlled trials of the drug in a larger sample. In addition, the use of probiotic biotherapy to maintain an appropriate intestinal flora may represent an effective early intervention for hyperglycemia. Unfortunately, there has been a shortage of relevant research on this possibility at the population level. This study was designed to determine the hypoglycemic effect and safety of both bifidobacteria and berberine administration to newly diagnosed patients with pre-diabetes or diabetes mellitus. METHODS/DESIGN: This is a multicenter, double-blind, randomized, and parallel-controlled study that includes a run-in period of 2 weeks and a treatment period of 16 weeks, which will be conducted between June 2015 and October 2018. The 300 randomized patients will be assigned to the following four groups for 16 weeks' treatment: Bifidobacterium, berberine, Bifidobacterium combined berberine, and placebo control groups. The primary outcome is the absolute value of fasting plasma glucose compared with baseline after 16 weeks of treatment. DISCUSSION: This is the first randomized controlled trial to determine the hypoglycemic effect and safety of both bifidobacteria and berberine administration to newly diagnosed patients with pre-diabetes or diabetes mellitus. It may provide support for the use of berberine and bifidobacteria in the treatment of diabetes. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03330184 . Retrospectively registered on 18 October 2017.
引用
- Ming J, Xu S, Liu C, et al. Effectiveness and safety of bifidobacteria and berberine in people with hyperglycemia: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29373989. doi:10.1186/s13063-018-2438-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。